Stock Analiz

Talphera, Inc. TLPH

Biotechnology: Pharmaceutical Preparations · IPO 2011 · data as of November 13, 2026

$0.91Market cap $47M
Open the interactive analysis →

Talphera, Inc. (TLPH) is a healthcare company listed in the US with a market value of about $47M. In fiscal year 2025 it had revenue of $28000 and net income of -$14M, a net margin of -51035.7%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -65% a year, a 5-year average ROIC of -103%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Talphera

Talphera is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2011. Revenue went from $5M in 2014 to $28000 in 2025, a decline of about 37.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 473% over three years (dilution for shareholders). It spends 21546% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B4.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-65.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-18369.1%
ROIC (5-yr avg.)-102.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$28000$0$651000—$3M$5M$2M$2M$8M$17M
Net income-$14M-$13M-$18M$48M-$35M-$40M-$53M-$47M-$52M-$43M
Free cash flow—-$13M-$18M-$29M-$32M-$40M-$55M-$30M-$32M-$33M
EPS (diluted)$-0.34$-0.50$-1.29$5.72$-5.86$-0.47$-0.67$-0.81$-1.10$-0.95
Net margin-51035.7%—-2826.0%—-1245.5%-745.5%-2325.9%-2192.0%-644.2%-248.6%
ROIC-62.5%-150.6%-119.7%-78.5%———-173.8%—-197.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $3.12, 245% above the current price; targets range from $3.00 to $3.50; the consensus rating is “none”; expected EPS is $-0.26 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Talphera stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Talphera pay a dividend?

Not currently.

Is Talphera a good stock to buy?

We do not give buy or sell advice. Talphera scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.